Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 7, 2010 Anand Chokkavelu	How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.
The Motley Fool September 24, 2010 Anand Chokkavelu	10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool December 29, 2006 Tim Beyers	Fool Fight: Johnson & Johnson vs. Procter & Gamble Both of these titans will need pain relief when this investing brawl is done. Here is what top investors have to say about these two consumer products giants.
The Motley Fool February 8, 2006 Nathan Slaughter	Best Blue Chip: Johnson & Johnson In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: it is easy to see why Johnson & Johnson, deserves to carry home the gold.
The Motley Fool October 13, 2009 Brian Orelli	J&J Needs to Get Drugged Up Medical devices and diagnostics pass by drugs as the main revenue source.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool April 18, 2007 Ryan Fuhrmann	Healthy Prognosis at Johnson & Johnson The long-term prognosis for JNJ remains healthy. Investors, take note.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool June 28, 2011 Eric Bleeker	Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales?
The Motley Fool September 30, 2009 Daniel Harrison	How Can Investors Be Missing This Kind of Value? As investors bid up the beaten-down names, it's time to look at the consistent hitters again.
The Motley Fool January 17, 2012 Brian Orelli	Pharma Focus Is Good For Your Portfolio Build your own portfolio.
The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool March 8, 2010 Jim Royal	5 Stocks for the Good Life The lowest-risk, most secure way to a great retirement may be to invest in blue-chip stocks.
The Motley Fool August 28, 2010 Todd Wenning	Dividend Report Card: Johnson & Johnson Does this health-care titan's dividend pass the test?
The Motley Fool October 18, 2005 Nathan Slaughter	Good Teamwork at J&J The health-care giant tops third-quarter estimates on strong sales of medical devices.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
The Motley Fool June 29, 2006 Claire Hsing	Great Companies, Great Returns For young investors focused on the long term, blue chips are best.
The Motley Fool April 19, 2005 Nathan Slaughter	Diagnosis: JNJ A-OK The health-care conglomerate beats expectations on strong international results.
The Motley Fool January 18, 2012	What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance.
The Motley Fool November 26, 2010 Brian Orelli	Get It Together, Johnson & Johnson Another day, another recall.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool October 14, 2008 Brian Orelli	Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.
The Motley Fool February 26, 2007 Tim Beyers	Fool on the Street: Healthy Heinz Apparently, selling health is healthy for business. But organic innovation isn't the most important factor in going global. Investors, take note.
The Motley Fool January 26, 2007 John Reeves	The Top Stocks of the Next 50 Years Even if you find a top stock of the next 50 years, the only way you'll benefit from those potential gains is if you hold for the long term and let the power of reinvested dividends work in your favor.
The Motley Fool July 14, 2009 Brian Orelli	J&J Eats a Hard Quarter Tough year-over-year comparisons are no match for the health care giant.
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool May 28, 2010 Brian Orelli	How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem?
The Motley Fool September 29, 2011 Brian Orelli	Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson.
The Motley Fool May 22, 2009 Brian Orelli	J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs.
The Motley Fool April 21, 2010 Brian Orelli	Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool February 2, 2010 Russ Krull	Defense! Defense! This stock screen looks for stocks that will hold up in a soft market.
The Motley Fool June 14, 2010	One Way to Protect Your Portfolio From a Market Downturn Rather than exit stocks completely, maybe now is the time for investors to focus on steady, stable, dividend-paying stocks.
The Motley Fool June 28, 2005 Lawrence Meyers	It's All Positive for PPDI Pharmaceutical Product Development continues to pump out the cash flow and rake in business. Investors, take note.
The Motley Fool February 28, 2011 Brian Orelli	Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo.
The Motley Fool September 11, 2010 Anand Chokkavelu	How Much of a Bargain Is Johnson & Johnson Stock Right Now? Let's take a look to see how cheap shares of Johnson & Johnson are trading, how consistent its performance has been, and what kind of growth profile it has -- both on an absolute and a relative basis.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool October 17, 2006 Brian Lawler	See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note.
The Motley Fool May 26, 2010 Brian Orelli	Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues.
The Motley Fool September 2, 2008 Todd Wenning	Supercharge Your Income With These Stocks Dividend stocks offer the best option, but you need to start now.
The Motley Fool January 26, 2010 Brian Orelli	Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years.
The Motley Fool August 3, 2005 Steven Mallas	JNJ: One to Monitor Johnson & Johnson might not exactly be a bargain, but it should always be on your stock watch list.
The Motley Fool October 13, 2008 Brian Orelli	Foolish Forecast: J&J's Diversity Counts Views you can use to get clues on tomorrow's news
The Motley Fool February 8, 2008 Mac Greer	Fool Video: Super Bowl Stocks and Bear Market Buys Who would win the Super Bowl of stocks? Does Home Depot have the right stuff for a bear market? Are Johnson & Johnson, Proctor & Gamble and Wal-Mart recession-proof? These questions and others are discussed in this video.
The Motley Fool June 16, 2006 Tim Beyers	Sharpen Your Dividend Edge There's a better way to know if your stock is heading higher.
The Motley Fool March 3, 2009 Nate Weisshaar	Invest Defensively: Look Abroad Invest like your favorite blue chips.
The Motley Fool January 28, 2011 Anand Chokkavelu	10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo.